As of 05 March 2025, the Health Technology Assessment (HTA) Council makes public its preliminary recommendation on the non-inclusion in the PNF and thus the non-government financing of hexavalent vaccine, for stakeholder feedback/comments. Overall, the HTA Council recognizes that hexavalent vaccines will result in a simpler immunization schedule and thus, better compliance and easier implementation. continue reading : HTA Council Preliminary Recommendation on Hexavalent Vaccine for active immunization of infants to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis b, and invasive disease due to Haemophilus influenzae type b
HTA Council Preliminary Recommendation on Fecal Immunohistochemical Test (FIT) for colorectal cancer in apparently healthy adults aged 50 years and above
As of 26 February 2025, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendation on the possible financing of Fecal immunohistochemical test (FIT) as an annual screening test for colorectal cancer for apparently healthy adults aged 50 years and above by the Department of Health (DOH) and/or PhilHealth, for stakeholder feedback/comments. Based continue reading : HTA Council Preliminary Recommendation on Fecal Immunohistochemical Test (FIT) for colorectal cancer in apparently healthy adults aged 50 years and above
HTA Council Preliminary Recommendation on High-risk Human Papillomavirus (HPV) DNA Test and Visual Inspection with Acetic Acid
Published on 11 February 2025 As of 11 February 2025, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendations on the possible financing of High Risk Human Papillomavirus (HrHPV) DNA Test and Visual Inspection with Acetic Acid (VIA) by Department of Health (DOH) and/or PhilHealth, for stakeholder feedback/comments. These health technologies were continue reading : HTA Council Preliminary Recommendation on High-risk Human Papillomavirus (HPV) DNA Test and Visual Inspection with Acetic Acid
CoronaVac COVID-19 Vaccine for Children 6 to 17 Years Old
Date of SOH Approval: 10 October 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of CoronaVac COVID-19 Vaccine for children continue reading : CoronaVac COVID-19 Vaccine for Children 6 to 17 Years Old
Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus
On 10 October 2022, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of both insulin glargine 10mL vial (100 IU/ml) and 3mL pre-filled pen (100 IU/ml) for patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) through their inclusion in the Philippine National Formulary (PNF). In continue reading : Insulin Glargine and Insulin Detemir for Type 1 and Type 2 Diabetes Mellitus